Compare KBSX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBSX | PRPO |
|---|---|---|
| Founded | 1976 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 42.0M |
| IPO Year | 2024 | 2000 |
| Metric | KBSX | PRPO |
|---|---|---|
| Price | $1.75 | $23.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.5K | ★ 120.8K |
| Earning Date | 11-18-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | $18.93 | $233.72 |
| Revenue Next Year | $13.80 | $22.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.81 | $16.40 |
| 52 Week High | $1.77 | $33.63 |
| Indicator | KBSX | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 69.07 | N/A |
| Support Level | $1.11 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.17 | 0.00 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 84.42 | 0.00 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.